Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Surgical resection of early stage hepatocellular carcinoma is standard clinical practice; however, most tumours recur despite surgery, and no perioperative intervention has shown a survival benefit. Neoadjuvant immunotherapy has induced pathological responses in multiple tumour types and might decre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet. Gastroenterology & hepatology 2022-03, Vol.7 (3), p.219-229
Hauptverfasser: Marron, Thomas U, Fiel, Maria Isabel, Hamon, Pauline, Fiaschi, Nathalie, Kim, Edward, Ward, Stephen C, Zhao, Zhen, Kim, Joel, Kennedy, Paul, Gunasekaran, Ganesh, Tabrizian, Parissa, Doroshow, Deborah, Legg, Meredith, Hammad, Ashley, Magen, Assaf, Kamphorst, Alice O, Shareef, Muhammed, Gupta, Namita T, Deering, Raquel, Wang, Wei, Wang, Fang, Thanigaimani, Pradeep, Mani, Jayakumar, Troncoso, Leanna, Tabachnikova, Alexandra, Chang, Christie, Akturk, Guray, Buckup, Mark, Hamel, Steven, Ioannou, Giorgio, Hennequin, Clotilde, Jamal, Hajra, Brown, Haley, Bonaccorso, Antoinette, Labow, Daniel, Sarpel, Umut, Rosenbloom, Talia, Sung, Max W, Kou, Baijun, Li, Siyu, Jankovic, Vladimir, James, Nicola, Hamon, Sara C, Cheung, Hung Kam, Sims, Jennifer S, Miller, Elizabeth, Bhardwaj, Nina, Thurston, Gavin, Lowy, Israel, Gnjatic, Sacha, Taouli, Bachir, Schwartz, Myron E, Merad, Miriam
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!